UNSPSC 51381514: Tolmetin glycine amide

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H18N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3RS348SV6U, chemically known as glycine, n-(2-(1-methyl-5-(4-methylbenzoyl)-1h-pyrrol-2-yl)acetyl)-, but more generally known as tolmetin glycine amide, which bears US NIH Compound Identifier 135911. European Medicines Agency schedules tolmetin glycine amide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11162MIG.

Most nations, for tariff purposes, schedule tolmetin glycine amide under HS 29339990. SMILES: CC1CCC(CC1)C(=O)C2CCC(N2C)CC(=O)NCC(=O)O.

UNSPSC 51381514 Tolmetin glycine amide is a Commodity code that shows minimal alignment with recent state and local procurement activity. The single identified recent opportunity — Seminole County, Florida's IFB60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023 — solicits naloxone and drug deactivation systems for community health initiatives, which falls entirely outside the scope of tolmetin glycine amide, a nonsteroidal anti-inflammatory drug. The mismatch between the code's nominal scope and the actual work being procured suggests the opportunity was misclassified in the procurement system rather than representing genuine demand under this Commodity code.

State and local governments do not appear to be actively soliciting tolmetin glycine amide through current procurement channels. The single recent record tied to this code represents pharmaceutical supply procurement in a health and safety context, not a pharmaceutical ingredient or finished drug product matching the code's definition. No additional opportunities, issuing bodies, geographic concentration, or representative solicitations support current market activity for this specific Commodity. A firm evaluating this code should verify whether state and local procurement systems are using it correctly or whether demand lies under an adjacent pharmaceutical or medical supply classification.